racemetirosine has been researched along with atrial natriuretic factor in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbella, Y; Cierco, M; Israel, A; Torres, M | 1 |
| Matsushima, K; Tozawa, Y | 1 |
| Bai, RY; Darvas, M; Davila, ML; Kim, K; Kinzler, KW; Papadopoulos, N; Riggins, GJ; Rothman, PB; Staedtke, V; Vogelstein, B; Zhou, S | 1 |
| Chen, SL; Zhang, DM | 1 |
1 review(s) available for racemetirosine and atrial natriuretic factor
| Article | Year |
|---|---|
Cytokine storms caused by novel coronavirus 2019 and treatment for cardiac injury.
Topics: alpha-Methyltyrosine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized; Antioxidants; Apoptosis; Atrial Natriuretic Factor; Azetidines; Benzyl Compounds; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Enzyme Inhibitors; Glucocorticoids; Glycoproteins; Humans; Hypoxia; Interleukin 1 Receptor Antagonist Protein; Myocardial Ischemia; Myocarditis; Myocytes, Cardiac; Oxidative Stress; Oxygen Inhalation Therapy; Respiration, Artificial; SARS-CoV-2; Sphingosine 1 Phosphate Receptor Modulators; Trypsin Inhibitors; Tumor Necrosis Factor Inhibitors | 2020 |
3 other study(ies) available for racemetirosine and atrial natriuretic factor
| Article | Year |
|---|---|
Further evidence for a dopaminergic involvement in the renal action of centrally administered atrial natriuretic peptide in rats.
Topics: alpha-Methyltyrosine; Analysis of Variance; Animals; Atrial Natriuretic Factor; Cerebral Ventricles; Desipramine; Diuresis; Dopamine; Injections, Intraventricular; Kidney; Male; Methyltyrosines; Natriuresis; Oxidopamine; Rats; Rats, Inbred Strains; Reference Values; Tyrosine 3-Monooxygenase | 1991 |
Peripheral 5-HT(2A)-receptor-mediated formation of an inhibitor of atrial natriuretic peptide binding involves inflammation.
Topics: Adrenergic alpha-Antagonists; alpha-Methyltyrosine; Animals; Atrial Natriuretic Factor; Catecholamines; Cyclooxygenase Inhibitors; Dexamethasone; Ditiocarb; Dopamine beta-Hydroxylase; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Indomethacin; Inflammation; Isatin; Ketanserin; Muscle, Smooth; Prazosin; Propranolol; Protein Binding; Rats; Rats, Wistar; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, Serotonin, 5-HT2A; Receptors, Angiotensin; Receptors, Serotonin; Reserpine; Ritanserin; Serotonin; Serotonin Receptor Agonists; Tyrosine 3-Monooxygenase; Urination; Vascular Resistance; Yohimbine | 2002 |
Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.
Topics: alpha-Methyltyrosine; Animals; Atrial Natriuretic Factor; Catecholamines; CD3 Complex; Cytokines; Epinephrine; Female; Humans; Immunotherapy, Adoptive; In Vitro Techniques; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid Cells; Norepinephrine; Receptors, Antigen, T-Cell; Syndrome; T-Lymphocytes | 2018 |